Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial

This study (called RENEGADE) is testing a minimally invasive procedure called Y90 radioembolization — where tiny radioactive beads are delivered through a blood vessel directly to a kidney tumor — as an alternative for people with early-stage kidney cancer who are not good candidates for surgery or traditional ablation. **You may be eligible if...** - You are 18 or older - You have kidney cancer (renal cell carcinoma) confirmed by imaging and biopsy - Your cancer is at an early stage (T1 or T2a, no spread to lymph nodes or other organs) - You have 1 to 2 solid kidney tumors - A multidisciplinary team has determined that surgery (partial removal) or thermal ablation is not a good option for you - Your expected survival is at least 12 months **You may NOT be eligible if...** - Your cancer has spread beyond the kidney - You have significant other health issues that would make this procedure unsafe - You are pregnant Talk to your doctor to see if this trial is right for you.